Based on our findings, we propose the following recommendations for clinicians when considering UBA: First, UBA is indicated in cases of demonstrable SUI. Intrinsic sphincter deficiency is not predictive of patient outcomes. Second, patients should be counseled on the risks, lack of long-term efficacy data, potential need for repeat injections, possible need for surgery for recurrent SUI, implications for future procedures, and pelvic imaging findings that may be observed after UBA. Third, UBA may be considered for initial management of SUI. Fourth, UBA is an option for patients with persistent or recurrent SUI after a sling procedure. Fifth, clinicians may prioritize UBA over surgery in specific patient populations. Sixth, polyacrylamide hydrogel demonstrates marginally improved safety and durability data over other available agents.
Keyphrases
- minimally invasive
- urinary incontinence
- coronary artery bypass
- end stage renal disease
- electronic health record
- palliative care
- ejection fraction
- big data
- high resolution
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- case report
- human health
- machine learning
- rectal cancer
- mass spectrometry
- clinical practice
- photodynamic therapy
- risk assessment
- acute coronary syndrome
- ultrasound guided
- artificial intelligence
- smoking cessation